THREAD
← Back

THREAD Launches New Rapid Migration Feature to Transition Active Clinical Studies from Legacy Technologies Eliminating Risk, Downtime and Costs

New platform features empower THREAD to transition active clinical trials from other technologies and integrate data from any source via a configurable migration solution

CARY, N.C., 28 OCT 2025 – Since its initial launch in 2018, THREAD’s no-code SaaS research platform and consulting services have been focused on innovating technology implementation and endpoint data capture to enable clinical research for everyone, everywhere. Today, the company announces new platform features enabling a fully configurable transition solution for active studies struggling with multiple technologies, data quality and patient retention challenges. The release focuses on meeting increased customer demand to upgrade from legacy providers to THREAD’s platform and has already been deployed successfully for initial clients.

It has historically been a challenge to deploy rescue migration technologies due to concerns around research study team disruption, downtime and data quality, even in situations where existing technology providers are not achieving core requirements or able to support the complexity of trials. Developed in partnership with clients and platform users, this feature enables active studies to upgrade their technology, consolidate systems and reduce budgets via the following approaches:

  • Transition from a legacy platform in hours with complete audit trail without disruption for research sites
  • Start participants at any point in their study journey with a seamless solution for research sites and participants
  • Accept and process data universally from any other legacy or partner system in any format
  • Enable real-time continuity without any downtime for research sites, participants and study teams

This feature has enabled THREAD to process and move over 1.2 million participant records from active global studies to its platform. Based on early use cases, THREAD now removes the risks and eliminates approximately 90% of costs associated with transitioning active studies to a new platform.

"Sponsors and CROs are engaging us to transition their studies away from legacy platforms to upgrade their studies to more modern technology, consolidate multiple systems into one, and decrease their overall trial costs,” said John Reites, Co-founder and CEO at THREAD. “We listened to our clients and worked with our platform users to enable a high-quality, fully configurable, no-downtime solution for them to transition their studies.”

Learn more about THREAD’s new active study migration solution by visiting https://discover.threadresearch.com/study-migration

##

About THREAD

THREAD’s® purpose is to leverage its clinical research platform to enable studies for everyone, everywhere. The companies’ uniquely combined clinical research technology and consulting services help life science organizations to design, operate, and scale next-generation research studies and electronic clinical outcome assessments (eCOA) programs for participants, sites, and study teams. Through its comprehensive platform and scientific expertise, THREAD empowers studies to be accessible, efficient, and centered on the patient. THREAD is recognized as a leader by Everest Group’s Decentralized Clinical Trial Product PEAK Matrix® Assessment 2021/2022/2023 and positioned in the Leader's Category of the 2022 IDC MarketScape for R&D Decentralized Clinical Trial Technology Solutions Vendor Assessment 2022. Visit THREADresearch.com to learn more.

Media Contact

Les Yates

THREAD

media@THREADresearch.com